Earnings Call InsightsTaysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advancesMar 19, 2026, 6:23 PM ETTaysha Gene Therapies, Inc. (TSHA) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Taysha Gene Therapies (TSHA) Q4 2025 Management View CEO Sean Nolan highlighted 2025 as "a year of significant execution" for Taysha, calling attention to "compelling REVEAL Phase I/II data across pediatric, adolescent and adult patients with Rett syndrome treated wi ...

Management also emphasized tolerability across studies to date. Nolan said both high- and low-dose TSHA-102 have continued to be generally well-tolerated, with no treatment-related serious adverse events or dose-limiting toxicities observed in patients treated in the REVEAL Phase I/II and REVEAL pivotal trials as of the March 2026 data cutoff.The company initiated the REVEAL pivotal trial in the fourth quarter of 2025 with dosing of the first patient. Nolan said multiple patients have now been dosed, enroll ...

Taysha Gene Therapies (NasdaqGS:TSHA) Q4 2025 Earnings call March 19, 2026 08:30 AM ET Company ParticipantsHayleigh Collins - Senior Director of Corporate Communications and Investor RelationsKamran Alam - CFOSean Nolan - CEOSukumar Nagendran - President and Head of R and DTazeen Ahmad - Managing Director of US Equity ResearchConference Call ParticipantsBiren Amin - Managing Director and Senior Research AnalystChris Raymond - Senior Biotech Research AnalystGil Blum - Senior AnalystJack Allen - AnalystKriste ...

Taysha Gene Therapies (NasdaqGS:TSHA) Q4 2025 Earnings call March 19, 2026 08:30 AM ET Company ParticipantsHayleigh Collins - Senior Director of Corporate Communications and Investor RelationsKamran Alam - CFOSean Nolan - CEOSukumar Nagendran - President and Head of R and DTazeen Ahmad - Managing Director of US Equity ResearchConference Call ParticipantsBiren Amin - Managing Director and Senior Research AnalystChris Raymond - Senior Biotech Research AnalystGil Blum - Senior AnalystJack Allen - AnalystKriste ...

Taysha Gene Therapies (NasdaqGS:TSHA) Q4 2025 Earnings call March 19, 2026 08:30 AM ET Speaker8Good day, and thank you for standing by. Welcome to the Taysha Gene Therapies full year 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand ...

Taysha Gene Therapies (NasdaqGS:TSHA) Q4 2025 Earnings call March 19, 2026 08:30 AM ET Speaker7Good day, and thank you for standing by. Welcome to the Taysha Gene Therapies full year 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand ...

FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the fiscal year ended December 31, 2025 OR (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) 3000 Pegasus Park Dr. ...

Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of March 2026 data cutof ; longer-term safety and ef icacy data from Part A of REVEAL Phase 1/2 trials expected in Q2 2026 Reached written alignment with FDA on proposed PPQ and comparability strategy for commercial TSHA-102 manufacturing to support planned BLA submission package Conference call and webcast today at 8:30 AM ET Exhibit 99.1 Taysha Gene Therapies Reports Full-Year ...

Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to <4 years with inclusion of ≥3 months of safety data in planned BLA submission to support potential for broad label; on track to complete dosing in Q2 2026 Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivota ...

Search fieldEntering text into the input field will update the search result belowEntering text into the input field will update the search result below ...